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The objective of this study was to validate a method for esti-
mating regional liver asialoglycoprotein (ASGP) receptor
amount from single blood samples using static SPECT with
99mTc-diethylenetriaminepentaacetic acid galactosyl human se-
rum albumin (99mTc-GSA). Methods: Based on a 2-compart-
ment nonlinear model, regional ASGP receptor amount could be
calculated from total liver ASGP receptor amount (Ro) and
regional GSA uptake at a specific time. Because Ro could be
estimated from single blood samples using an empiric formula,
regional GSA uptake obtained as a SPECT voxel count could be
converted to regional ASGP receptor amount by solving a non-
linear model equation. To validate this method, data from 62
patients with chronic liver disease underwent dynamic SPECT
(30 rotations per 30 min) and simultaneous multiblood sampling
and were analyzed by this method. Ro was calculated as the
sum of voxel values of parametric receptor images generated
from plasma concentration of GSA at 20 min and of static
SPECT images generated by merging dynamic SPECT data
(12–20 min). Ro was also estimated by fitting time–activity
curves (4–30 min) of plasma and whole liver to the nonlinear
model using the nonlinear regression method. Ro obtained from
the receptor image was compared with that from curve fitting in
relation to the results of hepatic function tests (indocyanine
green test, hepaplastin test, and branched-chain amino acids/
tyrosine plasma concentration ratio) and Child’s classification.
Results: Ros from the 2 methods showed a significant linear
correlation (r2  0.938; P  0.0001; slope  0.90; y-intercept 
1.5). Both Ros had significant correlations with the results of he-
patic function tests (P  0.001) and differed significantly among
the 3 groups of Child’s classification (P  0.0001). Conclusion:
The present method could provide a quantitative ASGP receptor
image without dynamic data acquisition. This approach could be
useful for quantitative evaluation of regional liver function and
estimation of residual liver function in hepatectomy.
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The asialoglycoprotein (ASGP) receptor is known to
reside on the surface of hepatocytes. Although its physio-
logic role has not been elucidated, past studies on serum
ASGP and the hepatic ASGP receptor suggested that this
receptor might be responsible for the metabolism of serum
glycoprotein (1). The receptor density in the liver was
closely related to serum ASGP level and hepatocellular
function (2). On the basis of these findings, a method for
evaluating hepatic function from the serum ASGP level has
been investigated (3). In nuclear medicine, the development
of 99mTc-labeled neoglycoalbumin (99mTc-NGA) for in vivo
use enabled the direct imaging of the liver ASGP receptor.
In conjunction with visual evaluation of the receptor image
and using time–activity curves of liver and cardiac blood
pool, kinetic model analyses have been performed to esti-
mate the hepatic receptor density. Vera et al. (4,5) devel-
oped a nonlinear 3-compartment model for in vivo estima-
tion of the receptor amount, and this method was validated
by direct comparison with results of in vitro receptor assay
using biopsied liver specimens. In addition to these studies,
other model analyses have been reported to be useful for
quantitative evaluation of liver function (6).
These nonlinear model analyses, however, could not be
applied to regional analysis, which could provide a quanti-
tative index of regional liver function. Regional liver uptake
and linear kinetic parameters, such as initial hepatic clear-
ance by Patlak plot, were reported to be useful methods for
analyzing regional ASGP receptor amount (7,8). Liver up-
take, however, could not have a linear relationship to the
receptor amount. On the other hand, initial hepatic clearance
had a linear relationship to the receptor amount (9), but
calculation of regional clearance by Patlak plot requires
dynamic SPECT data acquisition with fast rotation, which,
in turn, requires a rotating multidetector gamma camera
system that may not be available in every institution. In this
context, we have developed a method for generating a
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functional map of regional liver ASGP receptor amount
from a single blood sample and a single static SPECT scan,
based on a simplified 2-compartment nonlinear model that
incorporates nonlinear binding of ASGP receptor and a
99mTc-labeled ligand. In the first step of this method, total
liver ASGP receptor amount (Ro) was estimated from
plasma distribution volume of the ligand at a specific time,
based on an empiric formula. In the second step, regional
ASGP receptor amount was calculated using estimated Ro
by solving a nonlinear equation that described the receptor–
ligand binding on a voxel-by-voxel basis. This method was
validated and its clinical significance as a liver function test
was investigated on dynamic SPECT data from 62 patient
studies, comparing this method with fit to a standard model
from conventional liver function tests.
MATERIALS AND METHODS
Radiopharmaceutical
The radiolabeled NGA used in this study was 99mTc-diethylene-
triaminepentaacetic acid galactosyl human serum albumin (99mTc-
GSA; Nihon Mediphysics, Nishinomiya, Japan), a synthetic NGA
(molecular weight  76,000) with about 33 galactose residues and
DTPA conjugated for chelating 99mTc (10,11). 99mTc-GSA was
provided in a labeled form with 98% specific activity.
Patients
A total of 62 patients (26 female, 36 male), aged 18–77 y
(mean SD: 59 17) were included in the study: 21 with chronic
hepatitis (3 of whom had hepatocellular carcinoma), 34 with liver
cirrhosis (24 of whom had hepatocellular carcinoma), 2 with
cholangiocellular carcinoma, and 5 with metastatic liver tumors
(metastasized from breast in 1, gallbladder in 2, and colon in 2
patients). Patients were classified into 3 groups according to
Child’s criteria of the degree of liver dysfunction: A, mild; B,
moderate; and C, severe (12). Thirty-four patients were classified
in group A, 14 in group B, and 14 in group C.
Study Protocol
All patients were studied with 99mTc-GSA dynamic SPECT.
Dynamic SPECT studies were performed using a triple-head ro-
tating gamma camera system equipped with low-energy general-
purpose collimators and a dedicated data processing unit
(GCA9300A and GMS550; Toshiba Medical, Tokyo, Japan). The
in-plane spatial resolution of this system was 14 mm full width at
half maximum. After fasting overnight, the patient was placed in a
supine position so that the liver and lower part of the heart could
be within the field of view of the detectors. 99mTc-GSA (185
MBq/3 mg) was injected intravenously as a bolus. After confir-
mation that the entire liver was covered by the detectors’ view,
dynamic SPECT data acquisition was started 1 min after the
injection and continued for 30 rotations in a 120° back-and-forth
continuous rotation mode with an acquisition time of 1 min per
rotation. In each rotation, 90 projection data (30 projections per
detector) were recorded in a 64  64 matrix (pixel size  6.4 
6.4 mm). SPECT image reconstruction was performed with a
filtered backprojection method using a ramp filter after preprocess-
ing with a Butterworth filter (cutoff frequency  0.41 cycle per
centimeter; order of 8) to obtain 30 sets of 6.4-mm-thick transaxial
SPECT images. Attenuation and scatter corrections were not per-
formed. To generate a set of images equivalent to static SPECT,
projection data of dynamic SPECT (12–20 min) were merged.
The border of the liver was determined by a threshold percent-
age (42%) to the maximum voxel count in the liver on the recon-
structed transaxial images obtained from the 30th rotation in which
the liver was delineated most clearly. The time–activity curve of
whole liver was then generated on the basis of this volume of
interest. The threshold of 42% was determined as appropriate to
detect the border of liver correctly in a phantom study.
During SPECT data acquisition, peripheral venous blood sam-
pling (3 mL each) was performed at 2, 4, 6, 8, 10, 15, 20, 30, and
40 min after the injection. After centrifugation of the sampled
blood, 0.5 mL plasma was aliquoted into 2 plastic test tubes from
each sample. Together with the diluted solution of the injected
standard, radioactivity of the plasma was counted on a well-type
scintillation -counter (ARC500; Aloka, Tokyo, Japan) to calcu-
late plasma concentration of 99mTc-GSA as percentage of injected
dose per milliliter plasma. The actual injected dose was determined
by counting the radioactivity of the pre- and postinjection syringes
on a digital dose calibrator (IGC3; Aloka). A calibration coeffi-
cient for converting radioactivity measured on the dose calibrator
to that on the well-type scintillation counter was determined by
counting a standard solution on both measuring instruments.
Estimation of Total ASGP Receptor Amount Based on
a Nonlinear Model Fitting
The model used here for describing 99mTc-GSA kinetics was a
simple nonlinear model that consisted of extrahepatic plasma,
intrahepatic plasma, and specific bound compartments. The model
did not contain a plasma flow parameter to connect intra- and
extrahepatic plasma compartments. We assumed quasiequilibrium
between extra- and intrahepatic plasma compartments. Under this
assumption, the amount of GSA in the intrahepatic plasma could
be expressed simply by multiplying the plasma concentration of
GSA by the distribution volume of the intrahepatic plasma com-
partment. As for the receptor–GSA binding, second-order associ-
ation was assumed. Dissociation from the receptor binding or
metabolism of GSA from the liver was not considered in this study
(4). The schematic representation of the model is shown in Figure
1, and the implicit functions for describing the model system are
expressed as:
dBt/dt  kRo  BtHt/Vc Eq. 1
Nt  Vh  Ht/Vc Eq. 2
Lt  Nt  Bt Eq. 3
Ht  Do  Lt Eq. 4
Lit  C  Lt Eq. 5
Cpt  Ht/Vc Eq. 6
where B(t)  GSA amount in the specific bound compartment;
N(t)  GSA amount in the intrahepatic plasma compartment,
L(t)  GSA amount in the whole liver; H(t)  GSA amount in the
extrahepatic plasma compartment at time t; k  the second-order
association rate constant for the receptor-GSA binding; Ro  total
ASGP receptor amount; Vc  extrahepatic plasma volume; Vh 
intrahepatic plasma volume; C  the coefficient for converting the
liver dose to the SPECT count; and Do injected dose. The model
parameters Ro, Vc, Vh, and C were set to be adjustable, and k was
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fixed to a theoretic value (2.475 mL/nmol/min) determined from
the number of galactose residues attached to a GSA molecule (4).
Liver time–activity curve (Li(t)) and plasma time–concentration
curve (Cp(t)) were fitted to Equation 5 and Equation 6 from 4 to 30
min after injection, using the weighted nonlinear least squares
regression method (damping Gauss–Newton method) to estimate
the adjustable parameters. Initial estimates of the adjustable pa-
rameters were determined according to a graphic method (13).
Liver time–activity data and plasma time–concentration data were
weighted assuming a Poisson distribution. To solve the nonlinear
differential equation (Eq. 1), after setting initial conditions of the
compartments (H(0)  Do  Vc/(Vc 	 Vh); N(t)  Do  Vh/
(Vc 	 Vh); B(0)  0), a numeric integration algorithm (Runge–
Kutta–Fehlberg method) was applied. All calculation was per-
formed on a workstation (Dell Precision 410 with Windows NT;
Dell Computer Corp., Round Rock, TX) using a double-precision
floating point number system.
Estimation of Total ASGP Receptor Amount from
Single Blood Sample
Plasma concentration of GSA at each sampling time was con-
verted to apparent distribution volume in a unit of liter by dividing
injected dose (100%) by the plasma concentration (percentage
injected dose per liter). Each distribution volume and Ro obtained
by the nonlinear model analysis were then normalized by the
patient’s body surface area (BSA), calculated by Haycock’s for-
mula using patient weight (W) and height (H) (BSA  0.024265
H0.3964 W0.5378) (14), and linearly scaled to the value of standard
BSA (1.73 m2). This normalization was performed because both
blood concentration and ASGP receptor amount could be related to
patient body size. To determine an empiric formula that converts
the single-point plasma distribution volume of GSA to Ro, Ro was
plotted over plasma distribution volume for 6 sampling times of 8,
10, 15, 20, 30, and 40 min. The plots were fitted to various
functions, including exponential, power series, and logarithmic
function, to determine an appropriate empiric formula that could
express the relationship between single-sample plasma distribution
volume and Ro.
Functional Mapping of Regional ASGP Receptor
Amount
Functional mapping of regional ASGP receptor amount was
performed, on the basis of the kinetic model described previously,
using the static SPECT image generated by merging dynamic
SPECT projection images from 12 to 20 min. Some constraints on
the model were imposed to make calculation simple. Total ASGP
Ro was estimated from a single blood sample at 20 min on the
basis of the optimized empiric formula (see results section). The
constant k was fixed to the theoretic value. Total plasma distribu-
tion volume (Vc 	 Vh) was determined from the linear regression
equation between patient BSA and the total plasma distribution
volume determined by the model fitting (see results section), and
a ratio of Vh to total plasma distribution volume was fixed to the
mean of the model estimates. Because all model parameters (k, Ro,
Vc, Vh) were determined, calculation of specific bound GSA
amount in the liver (At) at middle SPECT scan times (tm) and Cp(t)
could be performed following Equations 1–4. Using At, specific
bound GSA amount in each voxel (Av) at tm was estimated
assuming Av was proportionate to the voxel counts. Using the
calculated Cp(t) as an input function, an implicit function describ-
ing regional GSA receptor binding and an equation held at tm were
expressed as:
dBrt/dt  kRr  BrtCpt Eq. 7
Brtm  Av Eq. 8
where Br(t)  specific bound GSA amount at time t and Rr 
ASGP receptor amount in a voxel. The value of Rr that satisfied
Equations 7 and 8 was determined by Newton’s method on a
voxel-by-voxel basis, and a parametric image of Rr was generated.
An initial value of Rr was set to the mean voxel receptor amount
calculated from Ro and the number of voxels in the liver. All
calculations were performed using a double-precision floating-
point number system on the workstation.
To validate the functional mapping from a single blood sample
and SPECT, the Ro obtained as a sum of the voxel values of a
parameter image was compared with that obtained from nonlinear
model fitting. To investigate the clinical significance of the ASGP
receptor amount as an index of liver function, Ro obtained by the
functional mapping and nonlinear model fitting was compared
with the results of conventional liver function tests. These tests
included the hepaplastin test, branched-chain amino acids/tyrosine
plasma concentration ratio, and blood retention of indocyanine
green at 15 min.
Statistical Analysis
Correlation analysis was performed by calculating Pearson’s
product–moment correlation coefficient (r) and corresponding P
value. To test the between-group difference of the mean values, a
t test with either equal or unequal variances was performed in a
pairwise fashion. P  0.05 was considered statistically significant
in all tests.
RESULTS
Estimation of Total ASGP Receptor Amount Based
on a Nonlinear Model Fitting
Liver time–activity and plasma time–concentration
curves could be fitted well to the model in all cases. In all
nonlinear least squares regressions, iterative calculation
FIGURE 1. Schematic representation of 2-compartment non-
linear model for describing GSA kinetics. L  amount of GSA in
liver; B  amount of specific bound GSA; N  amount of GSA
in intrahepatic plasma; H  amount of GSA in extrahepatic
plasma; Ro  total liver receptor amount; k  second-order
association rate constant; Vc  extrahepatic plasma volume;
Vh  intrahepatic plasma volume.
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ended with normal convergence and all adjustable parame-
ters could be determined with small error of the estimate
(20% in fractional error of the estimate). The correlation
coefficient (r2) between observed and calculated data ranged
from 0.9948 to 0.9999 (mean  SD  0.9993  0.0007).
Examples of nonlinear model fitting from 2 patients with
severe and mild liver dysfunction are shown in Figure 2.
Estimation of Total ASGP Receptor Amount from
Single Blood Sample
To determine the best formula to express the relationship
between Vd of GSA and Ro scaled to standard BSA, several
functions were tested by regression analysis. In these func-
tions, a logarithmic function was found to be the best in
goodness of fit and is expressed as:
Ro  P1  P2  lnVd  P3  Vd. Eq. 9
In Equation 9, P1–3 are the constants. When this function
was used for a regression formula, r2 between Vd and Ro
were 0.940 at sampling times 15–40 min after the injec-
tion of GSA. If Vd at sampling times 15 min was used for
regression, the plots were scattered and could not be fitted
well by any function. The result of regression analysis with
the logarithmic formula (Eq. 9) at 20 min after injection is
plotted in Figure 3 as an example, and the determined
constants for 8–40 min after injection are summarized in
Table 1.
Functional Mapping of Regional ASGP Receptor
Amount
To reduce the number of unknown parameters, several
constraints on the model parameters were imposed. In these
constraints, total plasma distribution volume (Vc 	 Vh)
was fixed to the predicted value based on the linear regres-
sion equation (Eq. 10) obtained from the correlation be-
FIGURE 2. Examples of nonlinear model fitting from 2 pa-
tients with severe (A) and mild (B) liver dysfunction. 99mTc-GSA
amount in liver and plasma are expressed as percentages of
injected dose.
FIGURE 3. Relationship between plasma distribution volume
(Vd) and total liver receptor amount (Ro) at 20 min after injection.
Solid curve represents regression curve based on Equation 9.
Both Vd and Ro were scaled to standard body surface area
(1.73 m2). ASGPR  asialoglycoprotein receptor.
TABLE 1
Constants Determined for Single-Sample Method
at Varying Sampling Times
Blood sampling
time (min) P1 P2 P3 r2 SEE
8 
66.8 60.0 7.8 0.845 12.0
10 
65.7 62.0 4.6 0.910 9.1
15 
59.1 55.8 2.5 0.955 6.5
20 
47.0 42.9 2.5 0.958 6.3
30 
36.8 34.2 1.8 0.956 6.4
40 
36.4 32.6 1.4 0.940 7.5
SEE  SE of estimate (nmol/1.73 m2).
478 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 44 • No. 3 • March 2003
tween estimated total plasma distribution volume (Vc 	
Vh, expressed in milliliters) by the nonlinear model analysis
and patient BSA (BSA, expressed in square meters).
Vc Vh 34.5 BSA 1312. Eq. 10
There was a weak but significant correlation between non-
linear model analysis and patient BSA (r  0.514; P 
0.001).
The ratio of Vh to total plasma distribution volume was
fixed to the mean of the model estimates (mean  SD 
18.7%  11.1%). The value of k was fixed to the theoretic
value (2.475 mL/nmol/min) as described in the methods
section. Ro was determined from single-sample plasma
distribution volume at 20 min after the injection following
Equation 9. Using these parameter values, Av and Cp(t)
were determined and Rr was calculated on the basis of
Equations 7 and 8. In all cases, mapping of Rr was com-
pleted in a few minutes and a parameter image was ob-
tained. An example is shown in Figure 4. To validate this
method, the total sum of Rr, which should equal the Ro, was
compared with Ro obtained by fitting liver time–activity
and time–plasma concentration curves to the model. Figure
5 shows the relationship between the sum of Rr and Ro. The
sum of Rr ranged from 15.1 to 159.8 nmol (mean  SD 
55.7  27.7), and Ro ranged from 9.2 to 138.0 nmol
(mean  SD  60.3  29.8). There was a significant
correlation (r2  0.938, P  0.001). The slope and y-
intercept of the regression line were 0.9 and 1.5 (nmol),
respectively.
The results of correlation analysis between the ASGP
receptor amount and conventional liver function tests are
summarized in Table 2, along with the correlation among
the liver function tests. The sum of Rr and Ro showed
statistically significant correlations (P  0.001) with the
liver function tests. In comparison with the Child’s classi-
fication, the sum of Rr and Ro differed significantly among
FIGURE 4. Images from 70-y-old man
with cholangioma, who received right por-
tal vein embolization (PE) to induce left
lobe hypertrophy before right lobectomy
and was studied with 99mTc-GSA before
and after PE. Asialoglycoprotein receptor
(ASGPR) image 2 mo after PE (D) showed
increased ASGPR amount in left lobe,
compared with baseline image (C). Voxel
value in receptor images is in pmol/mL
liver. Corresponding CT images (A and B)
before and after PE are references.
FIGURE 5. Total liver asialoglycoprotein receptor (ASGPR)
amounts calculated as sum of liver voxel values of generated
ASGP receptor images showed good correlation with those
from nonlinear model analysis on plasma and liver dynamic
SPECT data.
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the 3 groups (P  0.0001). ASGP receptor amounts ob-
tained as Ro by nonlinear model fitting were 75.4  21.0
(n  34), 39.8  6.9 (n  14); and 24.0  8.3 (n  14)
nmol in the groups A, B, and C, respectively. Those ob-
tained as the sum of Rr, however, were 80.8  24.5 (n 
34), 43.1  7.1 (n  14), and 27.8  7.2 (n  14) nmol in
groups A, B, and C, respectively (Fig. 6).
DISCUSSION
The model used in this study was a simplified version of
the 3-compartment model proposed by Vera et al. (4). The
main difference was in treatment of plasma flow parameter
and constraint on k. In our model, plasma flow was omitted,
assuming quasiequilibrium between intra- and extrahepatic
plasma compartments, and k was fixed to the theoretic value
calculated from the number of galactose residues attached to
a GSA molecule (4). At first, we tried the original Vera
model without these simplifications, but it was sometimes
difficult to estimate plasma flow parameter with only a
small error and to determine k and Ro separately. Among
the model parameters, k and Ro were highly correlated.
Because the injected dose was limited to 3 mg (40 nmol)
and the normal value of Ro was reported to be around 100
nmol (5), the injected dose could not saturate the total
receptor in some patients with good hepatic reserve. This
fact could be one reason for the difficulty in separate esti-
mation of k and Ro. When k was fixed to the theoretic value,
nonlinear model fitting became easy to converge and could
provide Ro with small error. Using 99mTc-GSA, Ha-Kawa
and Tanaka (15) also fixed Michaelis’s constant, which is
equivalent to k in a nonlinear model based on Michaelis–
Menten’s theory for describing nonlinear uptake by the
liver, to avoid correlation between Michaelis’s constant and
Rmax. This constraint was validated. As for hepatic plasma
flow parameter, even if the plasma flow parameter was
omitted and quasiequilibrium between intra- and extrahe-
patic plasma compartments was assumed instead, the esti-
mated value of receptor amount was not changed in our
preliminary study. From these results, we believed elimina-
tion of the plasma flow parameter and the constraint on k
could be justified.
The single-blood-sampling method for estimating Ro
originated in the method for estimating renal clearance in
nuclear nephrology (16,17). Because 99mTc-GSA is cleared
from blood only by the liver via receptor–ligand binding, we
hypothesized that blood retention at a specific time after
injection could be determined by the Ro, analogous to the
renal agent. The necessary assumption underlying this
method is that the tracer exists mainly in the blood and liver.
Because 99mTc-GSA has a molecular size similar to that of
albumin, a typical intravascular tracer, the assumption that
the distribution of the tracer is restricted to blood and liver
could be acceptable in the majority of clinical cases. In
addition, this assumption has already been made by other
investigators in constructing the kinetic models of radiola-
beled NGA (18,19) and seemed to have no serious adverse
effect on the model consistency. However, in patients with
massive ascites or protein-losing disease, there is no guar-
antee that this assumption is correct. We should be cautious
about applying this method to such patients.
To make it possible to generate a functional map of
regional ASGP receptor amount from a single static
SPECT, several constraints on the model were imposed.
These constraints might have introduced some bias into the
final estimate. However, the total sum of the voxel receptor
amount obtained from the parameter image showed good
correlation with the Ro obtained from nonlinear model
fitting of dynamic data. This result indicated that the main
parameter that determines 99mTc-GSA liver accumulation
could be the receptor amount and that fluctuation in other
parameters might bring about little effect on liver accumu-
lation of 99mTc-GSA. In theory, any time interval for ac-
quiring static SPECT data would be acceptable as far as the
assumptions made on the kinetic model are correct. How-
ever, it would be better to avoid initial uptake and late
phases (probably 10 min and 30 min after injection) in
which the liver time–activity curve has a relatively steep
rise and excretion of the tracer into the biliary system
TABLE 2







(%) ICG R15 (%)
Hepaplastin test (%) 0.679 0.517 — —
(P  0.001) (P  0.001)




(P  0.001) (P  0.001) (P  0.001)
BCAA/TYR ratio 0.691 0.638 0.624 
0.695
(P  0.001) (P  0.001) (P  0.001) (P  0.001)
ASGPR_NLS  asialoglycoprotein receptor (ASGPR) amount obtained from nonlinear model fitting; ASGPR_MAP  ASGPR amount
obtained from receptor image; ICG R15  blood retention of indocyanine green at 15 min; BCAA/TYR ratio  branched-chain amino
acids/tyrosine plasma concentration ratio.
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sometimes becomes apparent, especially in the case of good
liver function. Under these circumstances, the interval of
12–20 min was used in this study for merging dynamic
SPECT data to generate a static SPECT equivalent.
Because there is no noninvasive reference test available
for evaluating regional liver function, it is difficult to di-
rectly validate the clinical significance of the functional
mapping method. However, the significant correlations be-
tween Ro obtained by this method and the results of con-
ventional liver function tests could support the clinical
significance of this method as a quantitative method for
analyzing regional liver function. The assessment of re-
gional liver function by mapping ASGP receptors in the
liver would be useful not only for simulating and monitor-
ing postoperative hepatic functional state in candidates for
hepatectomy and in hepatectomized patients but for diag-
nosing benign focal liver diseases, such as focal nodular
hyperplasia, characterized by hepatocellular hyperplasia. It
would also be useful in transplantation for preoperative
assessment of living donor liver and postoperative monitor-
ing of transplanted liver.
In comparison with other methods for evaluating regional
function using 99mTc-GSA, such as regional liver uptake and
initial hepatic clearance (7,8), this method has several ad-
vantages. Dynamic SPECT with fast rotation is not needed,
and direct generation of the ASGP receptor map from a
single static SPECT with lower statistical noise is possible.
Moreover, this method could be more relevant for the as-
sessment of regional ASGP receptor amount because non-
linear binding of 99mTc-GSA and the receptor was consid-
ered, a factor not incorporated into other methods.
To measure the correct regional tracer dose by SPECT,
attenuation and scatter correction are indispensable. Unfor-
tunately, these corrections were not implemented in our
study because of the limitation of the gamma camera and
data processing system. In these circumstances, our data
could contain some inaccuracy in regional ASGP receptor
amount, especially in the deep part of the liver. The recent
advent of a practical approach to attenuation and scatter
correction has improved the accuracy of SPECT measure-
ment of regional tracer amount (20,21). If the system has
appropriate hardware and software, these techniques could
be incorporated into the functional mapping method to
improve accuracy in assessing regional liver function.
CONCLUSION
Based on a simple nonlinear model for 99mTc-GSA liver
kinetics, our proposed method could provide a quantitative
ASGP receptor image from a single blood sample and static
SPECT without dynamic data acquisition. The Ro obtained
as a sum of the voxel values of a parameter image showed
good correlation with that obtained from nonlinear model
fitting of blood and liver dynamic data. Total ASGP recep-
tor amount obtained from the receptor image and nonlinear
model fitting showed significant correlations with the results
of conventional liver function tests. This approach could be
useful for quantitative evaluation of regional liver function
and estimation of residual liver function in candidates for
hepatectomy.
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